SCHEMBL12409231

SCHEMBL12409231

NS(=O)(=O)c1ccc(CNc2nccn3c(-c4ccc(F)cc4)cnc23)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTK P33981 11/20 0.51
KDM4E B2RXH2 3/20 0.46
ALDH1A1 P00352 2/20 0.46
GAA P10253 2/20 0.46
MEN1 O00255 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
HPGD P15428 1/20 0.46
ALOX12 P18054 1/20 0.46
CYP2C19 P33261 1/20 0.46
HTT P42858 1/20 0.46
GFER P55789 1/20 0.46
KMT2A Q03164 1/20 0.46
NTRK1 P04629 1/20 0.44
NTRK3 Q16288 1/20 0.44
NTRK2 Q16620 1/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA9 Q16790 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12409269 0.91 TTK (0.52) TTKKDM4ECA1CA2CA9
SCHEMBL2181894 0.90 TTK (0.53) TTKKDM4ECA1CA2CA9
SCHEMBL12409233 0.90 TTK (0.53) TTKKDM4ENTRK1NTRK3NTRK2
SCHEMBL12409310 0.90 TTK (0.57) TTKKDM4ECA1CA2CA9
SCHEMBL12409306 0.88 SYK (0.49) TTKKDM4EALDH1A1GAAMEN1
SCHEMBL12409257 0.88 PI4KB (0.53) TTKNTRK1NTRK3NTRK2ZAP70
SCHEMBL3466302 0.87 CA2 (0.52) TTKKDM4EALDH1A1CYP1A2CYP2D6
SCHEMBL12409228 0.87 CA1 (0.52) TTKGAACA1CA2CA9
SCHEMBL12409248 0.87 ADORA3 (0.49) TTKMEN1KMT2ANTRK1ZAP70
SCHEMBL12409246 0.87 TTK (0.47) TTKKDM4ECA1CA2ZAP70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362018-B2 Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections BIOFOCUS DPI, LTD. (GB) 2013-01-29 US disclosed
US-8362018-B2 Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections BIOFOCUS DPI, LTD. (GB) 2013-01-29 US disclosed
US-20110166147-A1 IMIDAZOPYRAZINE COMPOUNDS BIOFOCUS DPI, LTD. (GB) 2011-07-07 US disclosed
US-20110166147-A1 IMIDAZOPYRAZINE COMPOUNDS BIOFOCUS DPI, LTD. (GB) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166147-A1 IMIDAZOPYRAZINE COMPOUNDS CYP3A5, HAVCR2, CYP3A43 TTK 3239/4885KDM4E 4116/4885ALDH1A1 750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.